Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
2 天之前 · Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley.
Halozyme CEO: Evotec Is Poised for Growth - MarketScreener
1 天前 · Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on February 20, 2024. Oct. 31. CI. -- Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on …
Watch Halozyme CEO: Evotec Is Poised for Growth - Bloomberg
1 天前 · Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology." (Source: Bloomberg)
Halozyme plans finance $2.1 takeover of Evotech in cash: report
Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in cash, Bloomberg reported Sunday, quoting Chief Executive Helen Torley.
Halozyme Confirms Proposal to Combine with Evotec for €11.00
5 天之前 · "The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond," said Helen Torley, president and chief ...
Helen Torley, M.B. Ch. B., M.R.C.P. - Halozyme
Helen Torley M.B. Ch. B., M.R.C.P. President and Chief Executive Officer. Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Torley joined Halozyme in January 2014 as …
Halozyme CEO Helen Torley sells shares worth over $1.7 million
In a recent transaction, Helen Torley, the President and CEO of Halozyme (NASDAQ: HALO) Therapeutics, Inc. (NASDAQ:HALO), sold a significant number of company shares.
Halozyme to Present at Upcoming Investor Conferences - Yahoo …
2024年8月28日 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate...
Halozyme to Host Investor Business Forum and Long-Term …
2024年1月12日 · On the call, Dr. Helen Torley, President and Chief Executive Officer will be joined by Mark Snyder, Chief Legal Officer and Nicole LaBrosse, Chief Financial Officer to present detailed guidance...
Halozyme to Host Investor Business Forum and Long-Term ... - BioSpace
2024年1月12日 · On the call, Dr. Helen Torley, President and Chief Executive Officer will be joined by Mark Snyder, Chief Legal Officer and Nicole LaBrosse, Chief Financial Officer to present detailed guidance around the patent dynamics that are expected to drive revenue durability of Halozyme's ENHANZE® drug delivery technology.